Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

OCTOBER 27, 2014

Pharmatest Services Ltd attends EORTC-NCI-AACR symposium in Barcelona

Pharmatest Services Ltd attends 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that will be held in Barcelona, Spain on November 18 – 21, 2014. In the symposium Pharmatest presents novel data with Bayer Healthcare about efficacy and mode of action of radium-223 dichloride in a mouse model of prostate cancer bone metastasis.

Pharmatest is presenting new exciting data at the meeting in collaboration with Bayer Pharma AG. The efficacy and mode-of-action of newly approved prostate cancer drug Xofigo® was studied in an osteoblastic prostate cancer bone metastasis model. Radium-223 dichloride therapy exhibits a dual mode-of-action that impacts on tumor growth and on tumor-induced bone reaction, both important players in the destructive vicious cycle of osteoblastic bone metastasis in prostate cancer.

Poster handout will be available here after the start of the poster session:

Radium-223 dichloride - Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis”.

If you would like to schedule a meeting with our representatives during the symposium, click here.